<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212716</url>
  </required_header>
  <id_info>
    <org_study_id>2015_65</org_study_id>
    <secondary_id>2016-004222-42</secondary_id>
    <secondary_id>PHRC_N -15-0442</secondary_id>
    <nct_id>NCT03212716</nct_id>
  </id_info>
  <brief_title>Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.</brief_title>
  <acronym>FLUNEXT</acronym>
  <official_title>Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the possibility to repropose marketed drugs as antiviral
      ones, based on their ability to reverse the transcriptomic signature of the infected cells.
      This strategy has to be considered is the context of emerging viral diseases and of increase
      of resistance to antivirals. Concerning infection by Influenza viruses, two main drugs were
      identified and evaluated on in vitro and in vivo models: etilefrine and diltiazem. Therefore,
      it will be assess the efficacy of these two drugs, compared to placebo, to treat severe flu.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of alive patients without detection of influenza A virus by RT-PCR in nasopharyngeal swabs,</measure>
    <time_frame>7 days after the beginning of the treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delay needed for the negativation of influenza A detection by RT-PCR</measure>
    <time_frame>up to 10days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>At 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilation</measure>
    <time_frame>an average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygenation (PaO2/FiO2 Ratio)</measure>
    <time_frame>once day for 10 days and at 28 days</time_frame>
    <description>Arterial blood samples for blood gas analysis are collected during the treatment period. The differences in the mean values of PaO2/FiO2 ratio are registered and analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>an average of 10 days in ICU and of 16 days in hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of extracorporeal membrane oxygenation (ECMO) if implemented.</measure>
    <time_frame>an average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic signature determined by the DNA microarray technology and analysed by bioinformatic tools</measure>
    <time_frame>Four time points : at inclusion, the first day after inclusion, the fourth day after inclusion, and the seventh day after inclusion</time_frame>
    <description>evaluation of the capacity of tested molecules to reverse the transcriptomic signature linked to the viral infection</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Flu</condition>
  <arm_group>
    <arm_group_label>etilefrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oseltamivir + etilefrine + placebo of diltiazem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diltiazem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oseltamivir + diltiazem + placebo of etilefrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oseltamivir + double placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oseltamivir + placebo of etilefrine and placebo of diltiazem</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>150 mg twice a day during 10 days (ANSM guidelines for severe flu).</description>
    <arm_group_label>etilefrine</arm_group_label>
    <arm_group_label>diltiazem</arm_group_label>
    <arm_group_label>oseltamivir + double placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etilefrine</intervention_name>
    <description>10 mg x3 per day during 10 days.</description>
    <arm_group_label>etilefrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>60 mgx3 per day during 10 days.</description>
    <arm_group_label>diltiazem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo of diltiazem or placebo of etilefrine</description>
    <arm_group_label>etilefrine</arm_group_label>
    <arm_group_label>diltiazem</arm_group_label>
    <arm_group_label>oseltamivir + double placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients hospitalized in intensive care units,

          -  for a suspicion of severe flu,

          -  with a pneumonia for less than 96 hours,

          -  and a respiratory failure defined by the necessity to resort to mechanical
             ventilation, invasive or not, or to deliver oxygen with a PaO2/FiO2&lt;200 mmHg.

        The inclusion is conditioned to the detection of Influenza A viruses rapid detection kit on
        nasopharyngeal swab.

        - Written informed consent

        Exclusion Criteria:

          -  No consent.

          -  Hypersensibility to Oseltamivir

          -  Negative rapid detection kit on nasopharyngeal swab.

          -  Symptoms for more than 96 hours.

          -  Moribund patients at inclusion.

          -  Pregnant/nursing woman.

          -  Patients already taking etilefrine or diltiazem in their personal home treatment.

          -  Patients having taken more than 3 intakes of oseltamivir before randomization.

        Contraindication to etilefrine or diltiazem:

          -  sinusal dysfunction without device.

          -  auriculo-ventricular heart block without device.

          -  Cardiogenic pulmonary oedema.

          -  bradycardia&lt;40/min.

          -  Non treated coronary insufficiency.

          -  Ventricular arrythmia.

          -  Hyperthyroidism.

          -  Uncontrolled Hypertension.

          -  Obstructive cardiomyopathy.

          -  Heart valve stenosis.

          -  Pheochromocytoma.

          -  Concomitant use of beta-blockers, antiarrythmic drugs, especially amiodarone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Poissy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Poissy, MD, PhD</last_name>
    <phone>03 20 44 44 95</phone>
    <phone_ext>+33</phone_ext>
    <email>julien_poissy@hotmail.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Djillali Annane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julien Poissy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Rimmelé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvie Vimeux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis Garot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infectiology</keyword>
  <keyword>Biology of infectious agents</keyword>
  <keyword>Flu</keyword>
  <keyword>Intensive care</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Etilefrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

